mRNA |
thalidomide |
CTRPv2 |
pan-cancer |
AAC |
-0.045 |
0.4 |
mRNA |
Irinotecan |
gCSI |
pan-cancer |
AAC |
-0.046 |
0.4 |
mRNA |
BMS-536924 |
GDSC1000 |
pan-cancer |
AAC |
0.026 |
0.4 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
azacitidine |
CTRPv2 |
pan-cancer |
AAC |
-0.03 |
0.4 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
BRD-K85133207 |
CTRPv2 |
pan-cancer |
AAC |
-0.03 |
0.4 |
mRNA |
lapatinib |
gCSI |
pan-cancer |
AAC |
-0.046 |
0.4 |
mRNA |
VX-680 |
GDSC1000 |
pan-cancer |
AAC |
-0.044 |
0.4 |
mRNA |
selumetinib:tretinoin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.4 |